Iovance Biotherapeutics, Inc.
NASDAQ:IOVABiotechnology
-$0.04 today
- Market cap
- $3.46B
- Beta
- 0.70
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.85
Volume 6.99M
Average 14.09M
IOVA Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Iovance Biotherapeutics, Inc.NASDAQ: IOVA
Research & Development · Q3 FY2026 · quarter ended Sep 2026
Research & development declines year over year
Q3 FY2026 research & development of $49.34M fell 34.4% year over year, behind the -19.7% change in trailing-twelve-month research & development. Sequentially, it fell 16.2% from the prior quarter. Over 3 fiscal years it compounded at +0.6% a year.
Context
- Research & development amounted to 114.0% of revenue in FY2025, down 58.1 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -34.4% toward the trailing-twelve-month pace of -19.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 300.27M USD
- Year-over-year change
- +6.4%
- 4-year CAGR
- +3.8%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 300.27M | +6.4% |
| FY2024 | 2024-12-31 | 282.34M | -17.9% |
| FY2023 | 2023-12-31 | 344.08M | +16.7% |
| FY2022 | 2022-12-31 | 294.78M | +13.8% |
| FY2021 | 2021-12-31 | 259.04M | — |
Research & Development vs competitors
How IOVA compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -19.7% is the 7th highest of 10, against a peer median of -0.6%.
- Research & development amounts to 63.8% of revenue for IOVA, versus a peer median of 82.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | €2.18B EUR | -0.6% | +9.6% | 82.6% | |
| LTM Jun 2026 | $1.78B USD | — | -34.5% | 43.1% | |
| LTM Sep 2026 | $378.58M USD | -9.4% | +7.3% | 27.9% | |
| LTM Mar 2026 | $259.11M USD | +17.2% | +34.4% | 67.2% | |
| LTM Sep 2026 | $252.23M USD | +33.2% | -5.7% | 138.2% | |
| LTM Sep 2026 | $241.88M USD | -19.7% | +0.6% | 63.8% | |
| LTM Sep 2026 | $236.54M USD | +35.6% | +95.7% | — | |
| LTM Dec 2025 | $223.39M USD | +26.2% | +32.9% | — | |
| LTM Mar 2026 | $100.48M USD | -23.9% | -30.4% | 1590.8% | |
| LTM Mar 2026 | $66.71M USD | -38.5% | -7.9% | — | |
| LTM Mar 2026 | $36.3M USD | -40.4% | -24.8% | 3629.9% | |
| Peer median (excluding IOVA) | — | -0.6% | +0.8% | 82.6% | |
Competitors are the stored peer set for IOVA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 1.19M | 164.07M | 263.5M |
| Cost of Revenue | 0 | 0 | 10.76M | 124M | 173.18M |
| Gross Profit | 0 | 0 | (9.57M) | 40.08M | 90.32M |
| Gross Margin | — | — | -804.5% | 24.4% | 34.3% |
| Research & Development | 259.04M | 294.78M | 344.08M | 282.34M | 300.27M |
| Selling, General & Admin | 83.66M | 104.1M | 106.92M | 153.02M | 152.32M |
| Operating Expenses | 342.7M | 398.88M | 450.99M | 435.35M | 488.53M |
| Depreciation & Amortization | 13.98M | 21.14M | 33.13M | 43.61M | 47.32M |
| EBITDA | (328.27M) | (371.77M) | (414.39M) | (331.4M) | (350.89M) |
| EBITDA Margin | — | — | -34851.9% | -202.0% | -133.2% |
| Operating Income | (342.7M) | (398.88M) | (460.56M) | (395.28M) | (398.21M) |
| Operating Margin | — | — | -38735.0% | -240.9% | -151.1% |
| Interest Income | 451K | 2.99M | 13.04M | 20.27M | 10.31M |
| Interest Expense | 0 | 2.99M | 0 | 0 | 0 |
| Other Income / Expenses | 451K | 2.99M | 13.04M | 20.27M | 5.16M |
| Income Before Tax | (342.25M) | (395.89M) | (447.52M) | (375.01M) | (393.05M) |
| Pre-Tax Margin | — | — | -37638.0% | -228.6% | -149.2% |
| Income Tax Expense | 0 | 0 | (3.48M) | (2.83M) | (2.07M) |
| Net Income | (342.25M) | (395.89M) | (444.04M) | (372.18M) | (390.98M) |
| Net Margin | — | — | -37345.4% | -226.8% | -148.4% |
| EPS (Basic) | (2.23) | (2.49) | (1.89) | (1.28) | (1.09) |
| EPS (Diluted) | (2.23) | (2.49) | (1.89) | (1.28) | (1.09) |
| Weighted Avg Shares | 153.41M | 159.26M | 235.13M | 289.88M | 357.35M |
| Weighted Avg Shares (Diluted) | 153.41M | 159.26M | 235.13M | 289.88M | 357.35M |
Iovance Biotherapeutics, Inc.
NASDAQ:IOVA
Intrinsic Alpha fair value
Locked
Current Price
$7.48
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.